[{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"75a6d88a-b107-4182-b4f0-b14a5142fd63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04175847","created_at":"2021-01-29T07:19:59.914Z","updated_at":"2024-07-02T16:35:18.633Z","phase":"Phase 1/2","brief_title":"A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04175847","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/14/2020","start_date":" 04/14/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-20"},{"id":"bf40d4c1-dcd3-4943-b816-d258ac3bd571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508334","created_at":"2022-08-19T17:10:11.271Z","updated_at":"2024-07-02T16:35:23.981Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05508334","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-10"}]